Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$184.8M
-24.9% from 2023
Prescriptions
59K
$3,149.04 per claim
Patients
6,773
2,397 prescribers
Total spending, 2024
$184.9M
$27,289.81 per patient
Medicare prescription drug plans paid $184.8M for Ambrisentan in 2024, for 58,699 prescriptions and refills to 6,773 patients (down 24.9% from 2023). The average cost per claim was $3,149.04.
California had the highest Medicare cost for Ambrisentan in 2024: $17.9M for 6,546 claims, followed by New York ($17.7M).
R J White, pulmonary disease in Rochester, NY, had the highest Medicare cost for Ambrisentan in 2024: 838 claims costing $3.3M.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| R J White Rochester, NY | Pulmonary Disease | 838 | 95 | $3.3M |
| Daniel J Lachant Rochester, NY | Pulmonary Disease | 516 | 57 | $2.3M |
| Rahul G Argula Charleston, SC |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 2,330 | 56,934 | 6,414 | $249.2M |
| 2023 | 2,351 | 58,103 | 6,453 | $246.0M |
| 2024 | 2,397 | 58,699 | 6,773 | $184.8M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 409 |
| 52 |
| $1.6M |
| Murali M Chakinala Saint Louis, MO | Pulmonary Disease | 485 | 50 | $1.5M |
| Naomi G Habib Phoenix, AZ | Pulmonary Disease | 382 | 44 | $1.5M |
| Namita Sood Sacramento, CA | Pulmonary Disease | 360 | 39 | $1.2M |
| Denise G Sese Charleston, SC | Pulmonary Disease | 331 | 41 | $1.1M |
| Frank Cefali New York, NY | Nurse Practitioner | 251 | 27 | $1.1M |
| Peter J Leary Seattle, WA | Pulmonary Disease | 331 | 36 | $1.1M |
| Harrison W Farber Boston, MA | Pulmonary Disease | 322 | 36 | $1.0M |
| Micah R Fisher Atlanta, GA | Pulmonary Disease | 362 | 37 | $954K |
| Michael J Cuttica Chicago, IL | Critical Care (Intensivists) | 239 | 27 | $923K |
| Terry A Fortin Durham, NC | Cardiology | 363 | 33 | $866K |
| Jean M Elwing Cincinnati, OH | Pulmonary Disease | 261 | 30 | $841K |
| Mark V Avdalovic Sacramento, CA | Pulmonary Disease | 219 | 26 | $840K |
| Stephanie P Gray Boston, MA | Physician Assistant | 244 | 33 | $802K |
| Charlie Lee Boston, MA | Physician Assistant | 261 | 33 | $788K |
| Shelley M Shapiro Los Angeles, CA | Cardiology | 253 | 25 | $771K |
| Charles Burger Jacksonville, FL | Pulmonary Disease | 201 | 20 | $732K |
| Emily Fedewa San Francisco, CA | Nurse Practitioner | 213 | 33 | $718K |
| Stephen C Mathai Baltimore, MD | Pulmonary Disease | 98 | 12 | $701K |
| Ronald J Oudiz Torrance, CA | Cardiology | 136 | 20 | $698K |
| Michael Mathier Pittsburgh, PA | Cardiology | 241 | 28 | $686K |
| Robert C Long Jackson, MS | Cardiology | 208 | 28 | $674K |
| Elizabeth Huffaker Bronx, NY | Nurse Practitioner | 163 | 22 | $674K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Cipla USA, Inc. CIPLA.NS | 13,818 | $48.6M |
| Sun Pharma Glob SUNPHARMA.NS | 13,390 | $48.4M |
| Actavis/Teva TEVA | 6,917 | $26.2M |
| Zydus Pharmaceu ZYDUSLIFE.NS | 10,302 | $24.4M |
| Aurobindo Pharm AUROPHARMA.NS | 5,811 | $16.3M |
| Mylan VTRS | 3,332 | $11.2M |
| Quallent Pharma | 2,675 | $9.1M |
| Apotex Corp | 2,466 | $632K |